Response to "can 'humanized' mice improve drug development in the 21st century?"

Trends in Pharmacological Sciences

Volumn 34, Issue 8, 2013, Pages 425-

  Bissig, Karl Dimiter ^a   Grompe, Markus ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITISINONE; TYROSINE;

BIOLOGICAL MODEL; CELL FUNCTION; DIET RESTRICTION; DISEASE SEVERITY; DRUG DEVELOPMENT; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; HISTORY OF MEDICINE; LETTER; LIVER CANCER; LIVER CELL; LIVER TOXICITY; LONG TERM SURVIVAL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHIMERA; DRUG DISCOVERY; HUMANS;

EID: 84881142146     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.06.001     Document Type: Letter

References (7)

1. G. Peltz Can 'humanized' mice improve drug development in the 21st century? Trends Pharmacol. Sci. 34 2013 255 260
2. K.D. Bissig Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment J. Clin. Invest. 120 2010 924 930
3. -/- mice Nat. Biotechnol. 25 2007 903 910
4. M. Al-Dhalimy Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I Mol. Genet. Metab. 75 2002 38 45
5. S.D. Cederbaum Amino acid metabolism A.E.H. Emery, Emery and Rimoin's Principles and Practice of Medical Genetics 3rd edn 1996 Churchill Livingstone 1872 1875
6. M. Dandri Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus Hepatology 33 2001 981 988
7. D.F. Mercer Hepatitis C virus replication in mice with chimeric human livers Nat. Med. 7 2001 927 933